Overview of Myeloproliferative Neoplasms
(also known as Myeloproliferative Disorders)

Essential thrombocythemia, polycythemia vera, and myelofibrosis are characterized by increased proliferation of myeloid, megakaryocytic, and erythroid cells.

Myeloproliferative neoplasms (MPNs), which are also known as myeloproliferative disorders (MPDs), share molecular and cellular characteristics but differ in phenotype and clinical presentation.1-3 Essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) are 3 Philadelphia chromosome–negative [Ph(–)] MPNs characterized by increased proliferation of myeloid, megakaryocytic, and erythroid cells.1,4,5 In these myeloproliferative disorders, unregulated proliferation may occur in 1 or more myeloid cell lines, including erythrocytes, platelets, and sometimes granulocytes.6,7

Overview of Myeloproliferative Neoplasms (also known as Myeloproliferative Disorders) - MPNConnect.com

References

  1. Vannucchi AM, Guglielmelli P, Tefferi A. CA Cancer J Clin. 2009;59:171-191.
  2. Tefferi A, Vardiman JW. Leukemia. 2008;22:14-22.
  3. Verstovsek S. Clin Cancer Res. 2010;16:1988-1996.
  4. Barbui T, Barosi G, Birgegard G, et al. J Clin Oncol. 2011;29:761-770.
  1. Marchioli R, Finazzi G, Specchia G, et al; for the CYTO-PV Collaborative Group. N Engl J Med. 2013;368:22-33.
  2. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Int J Hematol. 2010;91:165-173.
  3. Spivak JL. Ann Intern Med. 2010;152:300-306.